Summit Therapeutics SMMT Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -206.1%-111pp | -94.9%+507pp | -601.8%-527pp | -75.1%+33.8pp | |
| Liquidity | |||||
| Current ratio | 9.9×-0.3× | 10.2×+0.9× | 9.3×-7.6× | 16.9×+13.1× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×-1.3× | 1.4×-2.6× | 3.9×+3.9× | |
| Per Share | |||||
| Book value per share | $0.88+62.9% | $0.54+331% | $0.13-80.9% | $0.66+3.6% | |
| Valuation | |||||
| Market capitalization | $13.02B-1.1% | $13.16B+618% | $1.83B-38.6% | $2.98B+58.0% | |
| Price / book | 19.8×-14.1× | 33.9×+10.3× | 23.6×0.0× | 23.6×+0.9× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Summit Therapeutics's ratios come from?
- Every ratio is computed from Summit Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.